Generated: May 27, 2017
Which drugs does patent RE41393 protect, and when does it expire?
|Title:||Treatment of refractory tumors using epothilone derivatives|
|Abstract:||Methods of treating tumors in a mammal, especially a human that has demonstrated resistance to other chemotherapeutic agents, is disclosed. Specifically, methods of the present invention are effective in tumors that have initially been unresponsive to taxane therapy, or have developed resistance during the course of treatment. The methods of the present invention comprise administering epothilone derivatives selected from those represented by the formula: ##STR00001## The subject epothilone derivatives are advantageous in addition to their enhanced potency and effectiveness against tumors that have demonstrated resistance to therapy with taxane oncology agents in that they are efficacious upon oral administration.|
|Inventor(s):||Lee; Francis Y.F. (Yardley, PA)|
|Assignee:||Bristol-Myers Squibb Company (Princeton, NJ)|
Patent Claim Types:|
see list of patent claims
|Use; Composition; Delivery;|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Patented / Exclusive Use|
R-pharm Us Llc
|INJECTABLE;IV (INFUSION)||022065-001||Oct 16, 2007||RX||Yes||Yes||RE41393*PED||► Subscribe|
R-pharm Us Llc
|INJECTABLE;IV (INFUSION)||022065-002||Oct 16, 2007||RX||Yes||Yes||RE41393*PED||► Subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
Export unavailable in trial.
Subscribe for complete access.